These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35924860)

  • 1. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
    Pandya BJ; Chen CC; McGuiness CB; Sullivan L; Feng Q; Walsh E; Borate U
    Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
    Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
    Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
    Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
    Solana-Altabella A; Boluda B; Rodríguez-Veiga R; Cano I; Acuña-Cruz E; Blanco A; Marco-Ayala J; de la Puerta R; Díaz-González Á; Piñana JL; Sanz J; Sempere A; Cervera J; Barragán E; Sargas C; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
    Eur J Haematol; 2021 May; 106(5):724-733. PubMed ID: 33609315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
    Kabra M; Margotto L; Manuguid F
    Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
    Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
    Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
    Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
    Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
    Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy.
    Huggar D; Knoth RL; Copher R; Cao Z; Lipkin C; McBride A; LeBlanc TW
    Future Oncol; 2022 Oct; 18(32):3609-3621. PubMed ID: 36305495
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic burden of acute myeloid leukemia: a literature review.
    Redaelli A; Botteman MF; Stephens JM; Brandt S; Pashos CL
    Cancer Treat Rev; 2004 May; 30(3):237-47. PubMed ID: 15059647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
    Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
    J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States.
    Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Cong Z
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):573-580. PubMed ID: 29923428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
    Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
    J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
    Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
    Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare expenses for treatment of acute myeloid leukemia.
    Bewersdorf JP; Shallis RM; Wang R; Huntington SF; Perreault S; Ma X; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):641-650. PubMed ID: 31159602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.